MK-2866

• Product NameMK-2866
  CAS No.841205-47-8
  Purity99%
  Min Quantity1000Kilograms
  Price1~2
• View Contact Detail

• 
  Molecular Structure

Detailed Description

Ostarine(MK-2866), Enobosarm
Product Name: Ostarine(MK-2866)
Synonyms: Ostarine(MK-2866);MK-2866 Ostarine;(2S)-3-(4-Cyanophenoxy-2,3,5,6-d4)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide;((2s)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoroMethyl)phenyl]-2-hydroxy-2-MethylpropanaMide)
CAS:841205-47-8,1202044-20-9
MF: C19H10D4F3N3O3
Applications of SARM mk-2866/ostarine
Ostarine is a potent and tissue-selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis. These patent products for research purposes only use. Ostarine (GTx-024, MK-2866, Enobosarm, S-22) is an orally bioavailable nonsteroidal selective androgen receptor modulator. Therefore, ostarine can be used for treatment of conditions such as muscle wasting and osteoporosis.

Specification:
Item Specification Result
Appearance An odorless, almost white or white powder pass
Identificaton The retention time of the major peak is
confirm to the RS pass
Loss on Drying Not more than 0.5% 0.33%
Assay(HPLC) Not less than 99.0% 99.59%
Ignition residue Not more than 0.1% pass
Heavy metal Not more than 20 ppm pass
Name CAS NO. Usage
AICAR 2627-69-2 acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown
MK2866 841205-47-8 medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.
MK-677 15972-10-0 A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly
LGD-4033 1165910-22-4 pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
GW1516 317318-70-0 For obesity, diabetes, dyslipidemia and cardiovascular disease
Andarine(S4) 401900-40-0 partial agonist, intended mainly for treatment of benign prostatic hypertrophy
SR9009 1379686-30-2 under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice
SR9011 1379686-30-2 For obesity, diabetes, dyslipidemia and cardiovascular disease
RAD140 1182367-47-0 New generation for gaining mass and cutting edges
YK11 366508-78-3 YK11: a SARM and myostatin inhibitor in one
431579-34-9

• 
• MK-2866